之江生物股份回购达1.01%，2025年业绩预计大幅减亏

Group 1: Core Insights - The company has repurchased shares amounting to 1.01% of its total share capital, with a total repurchase amount of approximately 41.87 million yuan [1][3] - The company expects a significant narrowing of its net profit loss for 2025, projecting a loss between 32 million yuan and 47 million yuan, which represents a year-on-year reduction in loss of 63.13% to 74.89% [4] - The company has obtained medical device certification in Malaysia, valid until December 2030, facilitating its expansion into overseas markets [5] Group 2: Stock Performance - The company's stock price experienced a limit-up on January 26, 2026 [2] Group 3: Business Developments - The company continues to focus on an integrated strategy of "prevention, diagnosis, and treatment," with ongoing investments in innovative pharmaceuticals and AI healthcare [5]